Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors

Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus

Shi, Y., & Massagué, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00432-x · Cited by 5,860 · see citing works

TGFβ in Cancer

Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907 · see citing works

A small molecule–kinase interaction map for clinical kinase inhibitors

Fabian, M. A., Biggs, W., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M. B., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,901 · see citing works

Valvular heart disease associated with fenfluramine-phentermine

Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632 · see citing works

TGFβ2 knockout mice have multiple developmental defects that are non-overlapping with other TGFβ knockout phenotypes

Sanford, L. P., Ormsby, I., Groot, A. C. G.-D., Sariola, H., Friedman, R., Boivin, G. P., Cardell, E. L., & Doetschman, T. (1997) · Development · doi:10.1242/dev.124.13.2659 · Cited by 1,447 · see citing works

TGFβ: the molecular Jekyll and Hyde of cancer

Bierie, B., & Moses, H. L. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1926 · Cited by 1,262 · see citing works

Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease

Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 882 · see citing works

Physiological Actions and Clinical Applications of Transforming Growth Factor-β (TGF-β)

Roberts, A. B., & Sporn, M. B. (1993) · Growth Factors · doi:10.3109/08977199309029129 · Cited by 755 · see citing works

Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation

Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 714 · see citing works

Transforming Growth Factor-β Signaling Through the Smad Pathway: Role in Extracellular Matrix Gene Expression and Regulation

Verrecchia, F., & Mauviel, A. (2002) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2002.01641.x · Cited by 669 · see citing works

Role of transforming growth factor-β superfamily signaling pathways in human disease

Gordon, K. J., & Blobe, G. C. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.01.006 · Cited by 644 · see citing works

TGF-β signaling in vascular biology and dysfunction

Goumans, M., Liu, Z., & ten Dijke, P. (2008) · Cell Research · doi:10.1038/cr.2008.326 · Cited by 606 · see citing works

Abnormal angiogenesis but intact hematopoietic potential in TGF‐β type I receptor‐deficient mice

Larsson, J., Goumans, M., Sjöstrand, L. J., van Rooijen, M. A., Ward, D., Levéen, P., Xu, X., ten Dijke, P., Mummery, C. L., & Karlsson, S. (2001) · The EMBO Journal · doi:10.1093/emboj/20.7.1663 · Cited by 563 · see citing works

Expression of a Truncated, Kinase-Defective TGF-β Type II Receptor in Mouse Skeletal Tissue Promotes Terminal Chondrocyte Differentiation and Osteoarthritis

Serra, R. A., Johnson, M. D., Filvaroff, E. H., LaBorde, J. B., Sheehan, D. M., Derynck, R., & Moses, H. L. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.139.2.541 · Cited by 476 · see citing works

Regulation of cell proliferation by Smad proteins

ten Dijke, P., Goumans, M., Itoh, F., & Itoh, S. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10066 · Cited by 450 · see citing works

Possible Role of Valvular Serotonin 5-HT2B Receptors in the Cardiopathy Associated with Fenfluramine

Fitzgerald, L. W., Burn, T. C., Brown, B. S., Patterson, J. P., Corjay, M. H., Valentine, P. A., Sun, J., Link, J. R., Abbaszade, I. G., Hollis, J. M., et al. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26444-0 · Cited by 440 · see citing works

Evolving Concepts of Cardiac Valve Dynamics: The Continuum of Development, Functional Structure, Pathobiology, and Tissue Engineering

Schoen, F. J. (2008) · Circulation · doi:10.1161/circulationaha.108.805911 · Cited by 421 · see citing works

SD-208, a Novel Transforming Growth Factor β Receptor I Kinase Inhibitor, Inhibits Growth and Invasiveness and Enhances Immunogenicity of Murine and Human Glioma CellsIn vitroandIn vivo

Uhl, M., Aulwurm, S., Wischhusen, J., Weiler, M., Jing, Y., Almirez, R. G., Mangadu, R., Liu, Y.-W., Platten, M., Herrlinger, U., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1013 · Cited by 414 · see citing works

Valvular Myofibroblast Activation by Transforming Growth Factor-β

Walker, G. A., Masters, K. S. B., Shah, D. N., Anseth, K. S., & Leinwand, L. A. (2004) · Circulation Research · doi:10.1161/01.res.0000136520.07995.aa · Cited by 397 · see citing works

The type I BMP receptor BMPRIB is required for chondrogenesis in the mouse limb

Yi, S. E., Daluiski, A., Pederson, R., Rosen, V., & Lyons, K. M. (2000) · Development · doi:10.1242/dev.127.3.621 · Cited by 384 · see citing works

TGF‐β signaling: A tale of two responses

Rahimi, R. A., & Leof, E. B. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21501 · Cited by 371 · see citing works

Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity.

ten Dijke, P., Ichijo, H., Franzèn, P., Schulz, P. J., Saras, J., Toyoshima, H., Heldin, C., & Miyazono, K. (1993) · PubMed · Cited by 351 · see citing works

Valvular Heart Disease

Carabello, B. A., & Crawford, F. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707033370107 · Cited by 301 · see citing works

Transforming Growth Factor-β Signal Transduction in Angiogenesis and Vascular Disorders

Bertolino, P., Deckers, M. M. L., Lebrin, F., & ten Dijke, P. (2005) · CHEST Journal · doi:10.1378/chest.128.6_suppl.585s · Cited by 264 · see citing works

TGFβ-related pathways

Patterson, G. I., & Padgett, R. W. (2000) · Trends in Genetics · doi:10.1016/s0168-9525(99)01916-2 · Cited by 251 · see citing works

Inhibition of Gene Markers of Fibrosis with a Novel Inhibitor of Transforming Growth Factor-β Type I Receptor Kinase in Puromycin-Induced Nephritis

Grygielko, E. T., Martin, W. M., Tweed, C. W., Thornton, P., Harling, J. D., Brooks, D. P., & Laping, N. J. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.082099 · Cited by 193 · see citing works

TGF-β, Smad3 and the process of progressive fibrosis

Gauldie, J., Bonniaud, P., Sime, P. J., Ask, K., & Kolb, M. R. J. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350661 · Cited by 182 · see citing works

Cell biology of valvular interstitial cells.

Mulholland, M. D. L., & Gotlieb, A. I. (1996) · PubMed · Cited by 181 · see citing works

TGFβ‐stimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the pro‐migratory TGFβ switch

Liu, I. M., Schilling, S. H., Knouse, K. A., Choy, L., Derynck, R., & Wang, X. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.266 · Cited by 174 · see citing works

Signaling via the Tgf-β type I receptor Alk5 in heart development

Sridurongrit, S., Larsson, J., Schwartz, R. J., Ruiz‐Lozano, P., & Kaartinen, V. (2008) · Developmental Biology · doi:10.1016/j.ydbio.2008.07.038 · Cited by 158 · see citing works

Atrioventricular cushion transformation is mediated by ALK2 in the developing mouse heart

Wang, J., Sridurongrit, S., Dudáš, M., Thomas, P. S., Nagy, A. R., Schneider, M. D., Epstein, J. A., & Kaartinen, V. (2005) · Developmental Biology · doi:10.1016/j.ydbio.2005.07.035 · Cited by 158 · see citing works

Alk3/Bmpr1a Receptor Is Required for Development of the Atrioventricular Canal Into Valves and Annulus Fibrosus

Gaussin, V., Morley, G. E., Cox, L., Zwijsen, A., Vance, K. M., Emile, L., Tian, Y., Liu, J., Hong, C., Myers, D. C., et al. (2005) · Circulation Research · doi:10.1161/01.res.0000177862.85474.63 · Cited by 142 · see citing works

Drug-induced Valvulopathy: An Update

Elangbam, C. S. (2010) · Toxicologic Pathology · doi:10.1177/0192623310378027 · Cited by 133 · see citing works

TGF-β signaling in vascular biology and dysfunction

Marie-Jose, Goumans, M., Zhen, Liu, Peter, P., ten, & Dijke (2009) · Acta Scientiarum Naturalium Universitatis Sunyatseni · Cited by 116 · see citing works

A Novel Small-Molecule Inhibitor of Transforming Growth Factor β Type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth <i>In vivo</i> and Prevents Tumor Recurrence after Surgical Resection

Suzuki, E., Kim, S., Cheung, H.-K., Corbley, M. J., Zhang, X., Sun, L., Shan, F., Singh, J., Lee, W.-C., Albelda, S. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2389 · Cited by 113 · see citing works

5-Hydroxytryptamine (5HT)-induced valvulopathy: Compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats

Elangbam, C. S., Job, L. E., Zadrozny, L. M., Barton, J. C., Yoon, L. W., Gates, L. D., & Slocum, N. (2008) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2008.03.005 · Cited by 110 · see citing works

Nonoverlapping expression patterns of ALK1 and ALK5 reveal distinct roles of each receptor in vascular development

Seki, T., Hong, K., & Oh, S. P. (2005) · Laboratory Investigation · doi:10.1038/labinvest.3700376 · Cited by 108 · see citing works

Discovery of 4-{4-[3-(Pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): A Potent, Selective, and Orally Active Transforming Growth Factor-β Type I Receptor Inhibitor

Gellibert, F. J., de Gouville, A., Woolven, J. M., Mathews, N., Nguyen, V.-L., Ruault, C., Patikis, A. N., Grygielko, E. T., Laping, N. J., & Huet, S. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0509905 · Cited by 107 · see citing works

Transforming Growth Factor-β Regulates in Vitro Heart Valve Repair by Activated Valve Interstitial Cells

Liu, C. A., & Gotlieb, A. I. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.080365 · Cited by 104 · see citing works

Dominant-Negative ALK2 Allele Associates With Congenital Heart Defects

Smith, K., Joziasse, I. C., Chocron, S., van Dinther, M., Guryev, V., Verhoeven, M. C., Rehmann, H., van der Smagt, J. J., Doevendans, P. A., Cuppen, E. P. J. G., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.843714 · Cited by 103 · see citing works

Agammaglobulinemia

Wallenborn, P. A. (1960) · The Laryngoscope · doi:10.1288/00005537-196001000-00001 · Cited by 94 · see citing works

TGF-β inhibitors for the treatment of cancer

Lahn, M. M. F., Kloeker, S., & Berry, B. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.629 · Cited by 83 · see citing works

Essential functions of Alk3 during AV cushion morphogenesis in mouse embryonic hearts

Song, L., Fässler, R., Mishina, Y. M., Jiao, K., & Baldwin, H. S. (2006) · Developmental Biology · doi:10.1016/j.ydbio.2006.08.004 · Cited by 83 · see citing works

Endoglin and Alk5 regulate epithelial–mesenchymal transformation during cardiac valve formation

Mercado-Pimentel, M. E., Hubbard, A. D., & Runyan, R. B. (2006) · Developmental Biology · doi:10.1016/j.ydbio.2006.12.038 · Cited by 75 · see citing works

Optimization of a Dihydropyrrolopyrazole Series of Transforming Growth Factor-β Type I Receptor Kinase Domain Inhibitors: Discovery of an Orally Bioavailable Transforming Growth Factor-β Receptor Type I Inhibitor as Antitumor Agent

Li, H., McMillen, W. T., Heap, C. R., McCann, D., Yan, L., Campbell, R. M., Mundla, S. R., King, C.-H. R., Dierks, E. A., Anderson, B. D., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701199p · Cited by 68 · see citing works

Activin receptor-like kinase 2 can mediate atrioventricular cushion transformation.

Lai, Y.-T., Beason, K., Brames, G. P., Desgrosellier, J. S., Clegett, M. C., Shaw, M. V., Brown, C. B., & Barnett, J. (2000) · Developmental Biology · doi:10.1006/dbio.2000.9698 · Cited by 64 · see citing works

Cardiac Valvular Pathology: Comparative Pathology and Animal Models of Acquired Cardiac Valvular Diseases

Donnelly, K. B. (2008) · Toxicologic Pathology · doi:10.1177/0192623307312707 · Cited by 51 · see citing works

Inhibition of ALK5 Signaling Induces Physeal Dysplasia in Rats

Frazier, K. S., Thomas, R. A., Scicchitano, M. S., Mirabile, R. C., Boyce, R. W., Zimmerman, D. M., Grygielko, E. T., Nold, J. B., DeGouville, A.-C., Huet, S., et al. (2007) · Toxicologic Pathology · doi:10.1080/01926230701198469 · Cited by 49 · see citing works

Mitral and aortic valve disease associated with ergotamine therapy for migraine. Report of two cases and review of literature.

HAUCK, A. J., Edwards, W. D., Danielson, G. K., Mullany, C. J., & Bresnahan, D. R. (1990) · PubMed · Cited by 45 · see citing works

Rapid Generation of a High Quality Lead for Transforming Growth Factor-β (TGF-β) Type I Receptor (ALK5)

Goldberg, F. W., Ward, R. A., Powell, S. J., Debreczeni, J. E., Norman, R. A., Roberts, N. J., Dishington, A. P., Gingell, H., Wickson, K. F., & Roberts, A. L. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900807w · Cited by 45 · see citing works

Towards an anti-fibrotic therapy for scleroderma: targeting myofibroblast differentiation and recruitment

Leask, A. (2010) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-3-8 · Cited by 44 · see citing works

Gene expression profiling demonstrates that TGF-β1 signals exclusively through receptor complexes involving Alk5 and identifies targets of TGF-β signaling

Karlsson, G., Liu, Y., Larsson, J. T., Goumans, M., Lee, J., Thorgeirsson, S. S., Ringnér, M., & Karlsson, S. (2005) · Physiological Genomics · doi:10.1152/physiolgenomics.00303.2004 · Cited by 37 · see citing works

ALK5 inhibition in renal disease

Laping, N. J. (2003) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(03)00002-x · Cited by 30 · see citing works

Inhibition of ALK5 as a New Approach to Treat Liver Fibrotic Diseases

de Gouville, A., & Huet, S. (2006) · Drug News & Perspectives · doi:10.1358/dnp.2006.19.2.977444 · Cited by 30 · see citing works

Evaluation of glycosaminoglycans content and 5-hydroxytryptamine 2B receptor in the heart valves of Sprague-Dawley rats with spontaneous mitral valvulopathy – A possible exacerbation by dl-amphetamine sulfate in Fischer 344 rats?

Elangbam, C. S., Wehe, J. G., Barton, J. C., Krull, D., Nyska, A., Crabbs, T. A., & Kissling, G. E. (2006) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2006.08.001 · Cited by 26 · see citing works

Transforming Growth Factor-β Signaling in Immunity and Cancer

Batlle, E., & Massagué, J. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.024 · Cited by 2,366 · see citing works

Targeting the TGFβ signalling pathway in disease

Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466 · see citing works

Targeting TGF-β Signaling in Cancer

Colak, S., & ten Dijke, P. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.11.008 · Cited by 1,003 · see citing works

TGFβ biology in cancer progression and immunotherapy

Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944 · see citing works

Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer

Du, B., & Shim, J. S. (2016) · Molecules · doi:10.3390/molecules21070965 · Cited by 810 · see citing works

Navigating CAR-T cells through the solid-tumour microenvironment

Hou, A. J., Chen, L. C., & Chen, Y. Y. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00189-2 · Cited by 556 · see citing works

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

Lahn, M. M. F., Herbertz, S., Sawyer, J. S., Stauber, A. J., Gueorguieva, I., Driscoll, K. E., Estrem, S. T., Cleverly, A., Desaiah, D., Guba, S. C., et al. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s86621 · Cited by 558 · see citing works

Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

Lan, Y., Zhang, D., Xu, C., Hance, K. W., Marelli, B., Qi, J., Yu, H., Qin, G., Sircar, A., Hernández, V. M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5488 · Cited by 494 · see citing works

Big opportunities for small molecules in immuno-oncology

Adams, J. L., Smothers, J. F., Srinivasan, R., & Hoos, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4596 · Cited by 481 · see citing works

Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis

Jackstadt, R., van Hooff, S. R., Leach, J. D. G., Cortés-Lavaud, X., Lohuis, J. O., Ridgway, R. A., Wouters, V. M., Roper, J., Kendall, T. J., Roxburgh, C. S. D., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.003 · Cited by 427 · see citing works

Overcoming TGFβ-mediated immune evasion in cancer

Tauriello, D. V. F., Sancho, E., & Batlle, E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00413-6 · Cited by 377 · see citing works

TGF-β Signaling in Control of Cardiovascular Function

Goumans, M.-J., & ten Dijke, P. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022210 · Cited by 360 · see citing works

Transforming growth factor-β in myocardial disease

Frangogiannis, N. G. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00646-w · Cited by 348 · see citing works

Epithelial–mesenchymal transition: a new target in anticancer drug discovery

Marcucci, F., Stassi, G., & Maria, R. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.13 · Cited by 340 · see citing works

The fibrosis-cell death axis in heart failure

Piek, A., de Boer, R. A., & Silljé, H. H. W. (2016) · Heart Failure Reviews · doi:10.1007/s10741-016-9536-9 · Cited by 304 · see citing works

TGF ‐β as a driver of fibrosis: physiological roles and therapeutic opportunities

Budi, E. H., Schaub, J. R., Decaris, M. L., Turner, S., & Derynck, R. (2021) · The Journal of Pathology · doi:10.1002/path.5680 · Cited by 300 · see citing works

TGFβ inhibition restores a regenerative response in acute liver injury by suppressing paracrine senescence

Bird, T. G., Müller, M., Boulter, L., Vincent, D. F., Ridgway, R. A., Lopez-Guadamillas, E., Lu, W.-Y., Jamieson, T., Govaere, O., Campbell, A. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan1230 · Cited by 261 · see citing works

Clinical development of therapies targeting TGFβ: current knowledge and future perspectives

Ciardiello, D., Élez, E., Tabernero, J. M., & Seoane, J. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.009 · Cited by 270 · see citing works

Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma

Zhao, Y., Cao, J., Melamed, A., Worley, M. J., Gockley, A. A., Jones, D., Nia, H. T., Zhang, Y., Stylianopoulos, T., Kumar, A. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818357116 · Cited by 262 · see citing works

Targeting TGF-β Signaling for Therapeutic GainPreprint

Akhurst, R. J. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022301 · Cited by 243 · see citing works

First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma

Rodon, J. A., Carducci, M. A., Sepúlveda-Sánchez, J. M., Azaro, A., Calvo, E., Seoane, J., Braña, I., Sicart, E., Gueorguieva, I., Cleverly, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1380 · Cited by 235 · see citing works

Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape

Martin, C. J., Datta, A., Littlefield, C., Kalra, A., Chapron, C., Wawersik, S., Dagbay, K. B., Brueckner, C. T., Nikiforov, A., Danehy, F. T., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay8456 · Cited by 224 · see citing works

On-Target Anti-TGF-β Therapies Are Not Succeeding in Clinical Cancer Treatments: What Are Remaining Challenges?

Teixeira, A. F., ten Dijke, P., & Zhu, H. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00605 · Cited by 210 · see citing works

Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF

Mercer, P. F., Woodcock, H. V., Eley, J. D., Platé, M., Sulikowski, M. G., Durrenberger, P. F., Franklin, L., Nanthakumar, C. B., Man, Y., Genovese, F., et al. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-207429 · Cited by 206 · see citing works

Dissecting fibrosis: therapeutic insights from the small-molecule toolbox

Nanthakumar, C. B., Hatley, R. J. D., Lemma, S., Gauldie, J., Marshall, R. P., & Macdonald, S. J. F. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4592 · Cited by 206 · see citing works

Current and upcoming therapies to modulate skin scarring and fibrosis.

Coentro, J. Q., Pugliese, E., Hanley, G., Raghunath, M., & Zeugolis, D. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.08.009 · Cited by 184 · see citing works

TGF-β Signaling in Liver, Pancreas, and Gastrointestinal Diseases and Cancer

Gough, N. R., Xiang, X., & Mishra, L. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.064 · Cited by 204 · see citing works

Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?

Sweeney, M., Corden, B., & Cook, S. A. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201910865 · Cited by 195 · see citing works

Molecular and Cellular Aspects of Calcific Aortic Valve Disease

Towler, D. A. (2013) · Circulation Research · doi:10.1161/circresaha.113.300155 · Cited by 193 · see citing works

Targeting transforming growth factor-β receptors in pulmonary hypertension

Guignabert, C., & Humbert, M. J. C. (2020) · European Respiratory Journal · doi:10.1183/13993003.02341-2020 · Cited by 192 · see citing works

Human cardiac fibrosis-on-a-chip model recapitulates disease hallmarks and can serve as a platform for drug testing

Mastikhina, O., Moon, B., Williams, K., Hatkar, R., Gustafson, D., Mourad, O., Sun, X., Koo, M., Lam, A. Y. L., Sun, Y., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119741 · Cited by 190 · see citing works

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first‐in‐class transforming growth factor‐β receptor type I inhibitor

Yingling, J. M., McMillen, W. T., Yan, L., Huang, H., Sawyer, J. S., Graff, J., Clawson, D. K., Britt, K. S., Anderson, B. D., Beight, D. W., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.23795 · Cited by 187 · see citing works

Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung and tumor fibrosis

Wei, Y., Kim, T. J., Peng, D. H., Duan, D., Gibbons, D. L., Yamauchi, M., Jackson, J., Saux, C. J. L., Calhoun, C., Peters, J. I., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94624 · Cited by 185 · see citing works

TGF-β-induced fibrosis: A review on the underlying mechanism and potential therapeutic strategies

Ong, C. H., Tham, C. L., Harith, H. H., Firdaus, N., & Israf, D. A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174510 · Cited by 189 · see citing works

Eliminating METTL1‐mediated accumulation of PMN‐MDSCs prevents hepatocellular carcinoma recurrence after radiofrequency ablation

Zeng, X., Liao, G., Li, S., Liu, H., Zhao, X. H., Li, S., Lei, K., Zhu, S., Chen, Z., Zhao, Y., et al. (2022) · Hepatology · doi:10.1002/hep.32585 · Cited by 183 · see citing works

Therapeutic implications of cancer epithelial-mesenchymal transition (EMT)

Cho, E. S., Kang, H. E., Kim, N. H., & Yook, J. I. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-018-01108-7 · Cited by 179 · see citing works

Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment

Gulley, J. L., Schlom, J., Barcellos‐Hoff, M. H., Wang, X., Seoane, J., Audhuy, F., Lan, Y., Dussault, I., & Moustakas, A. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13146 · Cited by 178 · see citing works

A Perspective on the Development of TGF-β Inhibitors for Cancer Treatment

Huynh, L., Hipolito, C. J., & ten Dijke, P. (2019) · Biomolecules · doi:10.3390/biom9110743 · Cited by 172 · see citing works

Discovery of N -((4-([1,2,4]Triazolo[1,5- a ]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1 H -imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of TGF-β Type I Receptor Kinase as Cancer Immunotherapeutic/Antifibrotic Agent

Jin, C. H., Krishnaiah, M., Sreenu, D., Subrahmanyam, V. B., Rao, K. S., Lee, H. J., Park, S., Park, H., Lee, K., Sheen, Y. Y., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500115w · Cited by 168 · see citing works

Development of an ALK2-Biased BMP Type I Receptor Kinase Inhibitor

Mohedas, A. H., Xing, X., Armstrong, K. A., Bullock, A. N., Cuny, G. D., & Yu, P. B. (2013) · ACS Chemical Biology · doi:10.1021/cb300655w · Cited by 164 · see citing works

Therapeutic Targets for the Treatment of Cardiac Fibrosis and Cancer: Focusing on TGF-β Signaling

Parichatikanond, W., Luangmonkong, T., Mangmool, S., & Kurose, H. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00034 · Cited by 151 · see citing works

Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer

Stüber, T. N., Monjezi, R., Wallstabe, L., Kühnemundt, J., Nietzer, S., Dandekar, G., Wöckel, A., Einsele, H., Wischhusen, J., & Hudecek, M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000676 · Cited by 146 · see citing works

Enhancing Adoptive Cell Therapy of Cancer through Targeted Delivery of Small-Molecule Immunomodulators to Internalizing or Noninternalizing Receptors

Zheng, Y., Tang, L., Mabardi, L., Kumari, S., & Irvine, D. J. (2017) · ACS Nano · doi:10.1021/acsnano.7b00078 · Cited by 145 · see citing works

A Selective Transforming Growth Factor-β Ligand Trap Attenuates Pulmonary Hypertension

Yung, L., Nikolić, I., Paskin-Flerlage, S. D., Pearsall, R. S., Kumar, R., & Yu, P. B. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201510-1955oc · Cited by 144 · see citing works

Intracellular and extracellular TGF-β signaling in cancer: some recent topics

Miyazono, K., Katsuno, Y., Koinuma, D., Ehata, S., & Morikawa, M. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0646-8 · Cited by 141 · see citing works

TGFβ control of immune responses in cancer: a holistic immuno-oncology perspective

Nixon, B. G., Gao, S., Wang, X., & Li, M. O. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00796-z · Cited by 138 · see citing works

TGFβ2 and TGFβ3 isoforms drive fibrotic disease pathogenesis

Sun, T., Huang, Z., Liang, W.-C., Yin, J., Lin, W. Y., Wu, J., Vernes, J.-M., Lutman, J., Caplazi, P., Jeet, S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0407 · Cited by 134 · see citing works

Targeting immunosuppression by TGF-β1 for cancer immunotherapy

de Streel, G., & Lucas, S. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114697 · Cited by 129 · see citing works

Fibroblast-enriched endoplasmic reticulum protein TXNDC5 promotes pulmonary fibrosis by augmenting TGFβ signaling through TGFBR1 stabilization

Lee, T.-H., Yeh, C., Lee, Y.-T., Shih, Y.-C., Chen, Y.-T., Hung, C., You, M.-Y., Wu, P., Shentu, T., Huang, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18047-x · Cited by 127 · see citing works

Characterization and Validation of a Human 3D Cardiac Microtissue for the Assessment of Changes in Cardiac Pathology

Archer, C. R., Sargeant, R., Basak, J., Pilling, J. E., Barnes, J. R., & Pointon, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-28393-y · Cited by 126 · see citing works

Mechanisms of Normal Tissue Injury From Irradiation

Citrin, D. E., & Mitchell, J. B. (2017) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2017.04.001 · Cited by 125 · see citing works

TGFβ, smooth muscle cells and coronary artery disease: a review

Low, E. L., Baker, A. H., & Bradshaw, A. C. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.09.004 · Cited by 122 · see citing works

Isorhamnetin Inhibits Liver Fibrosis by Reducing Autophagy and Inhibiting Extracellular Matrix Formation via the TGF-β1/Smad3 and TGF-β1/p38 MAPK Pathways

Liu, N., Feng, J., Lu, X., Yao, Z., Liu, Q. H., Lv, Y., Han, Y., Deng, J., & Zhou, Y. (2019) · Mediators of Inflammation · doi:10.1155/2019/6175091 · Cited by 121 · see citing works

Integrin αvβ8–expressing tumor cells evade host immunity by regulating TGF-β activation in immune cells

Takasaka, N., Seed, R. I., Cormier, A., Bondesson, A. J., Lou, J., Elattma, A., Ito, S., Yanagisawa, H., Hashimoto, M., Ma, R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122591 · Cited by 119 · see citing works

Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment

Hanks, B. A., Holtzhausen, A., Evans, K. S., Jamieson, R., Gimpel, P., Campbell, O. M., Hector-Greene, M., Sun, L., Tewari, A. K., George, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65745 · Cited by 120 · see citing works

Cancer Immunotherapy: Selected Targets and Small‐Molecule Modulators

Weinmann, H. (2016) · ChemMedChem · doi:10.1002/cmdc.201500566 · Cited by 122 · see citing works

Roles of TGF-β signaling pathway in tumor microenvirionment and cancer therapy

Zhao, H., Wei, J., & Sun, J. M. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107101 · Cited by 117 · see citing works

Ursodeoxycholic acid reduces antitumor immunosuppression by inducing CHIP-mediated TGF-β degradation

Shen, Y., Lu, C., Song, Z., Qiao, C., Wang, J., Chen, J., Zhang, C., Zeng, X., Ma, Z., Chen, T., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31141-6 · Cited by 121 · see citing works

Therapeutic potential of tumor-associated neutrophils: dual role and phenotypic plasticity

Zhou, Y., Shen, G., Zhou, X., & Li, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02242-7 · Cited by 116 · see citing works

Endoplasmic reticulum protein TXNDC5 promotes renal fibrosis by enforcing TGF-β signaling in kidney fibroblasts

Chen, Y., Jhao, P.-Y., Hung, C., Wu, Y., Lin, S., Chiang, W., Lin, S., & Yang, K. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143645 · Cited by 114 · see citing works

Attenuated development of cardiac fibrosis in left ventricular pressure overload by SM16, an orally active inhibitor of ALK5

Engebretsen, K. V. T., Skårdal, K., Bjørnstad, S., Marstein, H. S., Skrbic, B., Sjaastad, I., Christensen, G., Bjørnstad, J. L., & Tønnessen, T. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.08.008 · Cited by 110 · see citing works

Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study

Kovacs, R. J., Maldonado, G., Azaro, A., Fernández, M. S., Romero, F. L., Sepulveda-Sánchez, J. M., Corretti, M., Carducci, M., Dolan, M., Gueorguieva, I., et al. (2015) · Cardiovascular Toxicology · doi:10.1007/s12012-014-9297-4 · Cited by 108 · see citing works

Non-proliferative and Proliferative Lesions of the Cardiovascular System of the Rat and Mouse

Berridge, B. R., Mowat, V., Nagai, H., Nyska, A., Okazaki, Y., Clements, P., Rinke, M., Snyder, P. W., Boyle, M. C., & Wells, M. Y. (2016) · Journal of Toxicologic Pathology · doi:10.1293/tox.29.3s-1 · Cited by 106 · see citing works

Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors

Fujiwara, Y., Nokihara, H., Yamada, Y., Yamamoto, N., Sunami, K., Utsumi, H., Asou, H., Takahashi, O., Ogasawara, K., Gueorguieva, I., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2895-4 · Cited by 101 · see citing works

A Potent Pan-TGFβ Neutralizing Monoclonal Antibody Elicits Cardiovascular Toxicity in Mice and Cynomolgus Monkeys

Mitra, M. S., Lancaster, K., Adedeji, A. O., Palanisamy, G. S., Dave, R. A., Zhong, F., Holdren, M. S., Turley, S. J., Liang, W., Wu, Y., et al. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfaa024 · Cited by 101 · see citing works

Transforming growth factor β and its role in heart disease

Liu, G., Ma, C., Yang, H., & Zhang, P.-Y. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4246 · Cited by 97 · see citing works

Immunotherapy for advanced hepatocellular carcinoma, where are we?

Li, Z., Ding, J., Li, H., Wang, Z., & Wu, J. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188441 · Cited by 94 · see citing works

Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor–Prolyl Hydroxylase Inhibitor for Anemia

Ariazi, J. L., Duffy, K. J., Adams, D. F., Fitch, D. M., Luo, L., Pappalardi, M. B., Biju, M. P., DiFilippo, E. H., Shaw, T., Wiggall, K., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.242503 · Cited by 93 · see citing works

Selective Targeting of TGF-β Activation to Treat Fibroinflammatory Airway Disease

Minagawa, S., Lou, J., Seed, R. I., Cormier, A., Wu, S., Cheng, Y., Murray, L., Tsui, P., Connor, J., Herbst, R., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008074 · Cited by 90 · see citing works

Inflammation, Fibrosis and Cancer: Mechanisms, Therapeutic Options and Challenges

Wu, B., Sodji, Q. H., & Oyelere, A. K. (2022) · Cancers · doi:10.3390/cancers14030552 · Cited by 90 · see citing works

Targeting small molecule drugs to T cells with antibody-directed cell-penetrating gold nanoparticles

Yang, Y.-S. S., Moynihan, K. D., Bekdemir, A., Dichwalkar, T., Noh, M. M., Watson, N., Melo, M. B., Ingram, J. R., Suh, H., Ploegh, H. L., et al. (2018) · Biomaterials Science · doi:10.1039/c8bm01208c · Cited by 86 · see citing works

Transforming growth factor-β receptors: versatile mechanisms of ligand activation

Chia, Z. J., Cao, Y.-N., Little, P. J., & Kamato, D. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01235-6 · Cited by 92 · see citing works

TGFβ signaling pathways in human health and disease

Chen, P., Qin, L., & Simons, M. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1113061 · Cited by 84 · see citing works

TGF-β signaling networks in the tumor microenvironment

Chan, M. K.-K., Chung, J. Y.-F., Tang, P. C.-T., Chan, A. S.-W., Ho, J. Y.-Y., Lin, T. P.-T., Chen, J., Leung, K.-T., To, K.-F., Lan, H.-Y., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215925 · Cited by 90 · see citing works

Physiological, pharmacological and toxicological considerations of drug‐induced structural cardiac injury

Cross, M. J., Berridge, B. R., Clements, P., Cove-Smith, L., Force, T. L., Hoffmann, P., Holbrook, M., Lyon, A. R., Mellor, H. R., Norris, A. A., et al. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12979 · Cited by 81 · see citing works

TGFβ signaling networks in ovarian cancer progression and plasticity

Kumari, A., Shonibare, Z., Monavarian, M., Arend, R. C., Lee, N. Y., Inman, G. J., & Mythreye, K. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10077-z · Cited by 76 · see citing works

Defining a therapeutic window for the novel TGF ‐β inhibitor LY 2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model

Gueorguieva, I., Cleverly, A., Stauber, A. J., Pillay, N. S., Rodon, J. A., Miles, C., Yingling, J. M., & Lahn, M. M. F. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12256 · Cited by 77 · see citing works

Armored bicistronic CAR T cells with dominant-negative TGF-β receptor II to overcome resistance in glioblastoma

Li, N., Rodriguez, J. L., Yin, Y., Logun, M. T., Zhang, L., Yu, S., Hicks, K., Zhang, J. V., Zhang, L., Xie, C., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.07.020 · Cited by 74 · see citing works

Therapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppression

van den Bulk, J., de Miranda, N. F. C. C., & ten Dijke, P. (2021) · Clinical Science · doi:10.1042/cs20201236 · Cited by 75 · see citing works

IL-13Rα2/TGF- β bispecific CAR-T cells counter TGF- β -mediated immune suppression and potentiate anti-tumor responses in glioblastoma

Hou, A. J., Shih, R. M., Uy, B. R., Shafer, A. M., Chang, Z. L., Comin-Anduix, B., Güemes, M., Galić, Z., Phyu, S. M., Okada, H., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae126 · Cited by 77 · see citing works

Epigallocatechin gallate (EGCG) suppresses epithelial-Mesenchymal transition (EMT) and invasion in anaplastic thyroid carcinoma cells through blocking of TGF-β1/Smad signaling pathways

Li, T., Zhao, N., Lu, J., Zhu, Q., Liu, X., Hao, F., & Jiao, X. (2019) · Bioengineered · doi:10.1080/21655979.2019.1632669 · Cited by 71 · see citing works

Targeting epithelial–mesenchymal plasticity in cancer: clinical and preclinical advances in therapy and monitoring

Bhatia, S., Monkman, J. H., Toh, A. K. L., Nagaraj, S. H., & Thompson, E. W. (2017) · Biochemical Journal · doi:10.1042/bcj20160782 · Cited by 73 · see citing works

The Role of Breast Cancer Stem Cells as a Prognostic Marker and a Target to Improve the Efficacy of Breast Cancer Therapy

Scioli, M. G., Storti, G., D’Amico, F., Gentile, P., Fabbri, G., Cervelli, V., & Orlandi, A. (2019) · Cancers · doi:10.3390/cancers11071021 · Cited by 70 · see citing works

TGF ‐β superfamily co‐receptors in cancer

Pawlak, J. B., & Blobe, G. C. (2021) · Developmental Dynamics · doi:10.1002/dvdy.338 · Cited by 68 · see citing works

Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin αvβ6 inhibitor, in healthy participants

Maden, C. H., Fairman, D., Chalker, M., Costa, M. J., Fahy, W. A., Garman, N., Lukey, P. T., Mant, T., Parry, S., Simpson, J. K., et al. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2435-3 · Cited by 65 · see citing works

Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy

Tschernia, N. P., & Gulley, J. L. (2022) · BioDrugs · doi:10.1007/s40259-022-00521-1 · Cited by 61 · see citing works

Principles of the activin receptor signaling pathway and its inhibition

Lodberg, A. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.04.001 · Cited by 62 · see citing works

Good and bad sides of TGFβ-signaling in myocardial infarction

Euler, G. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00066 · Cited by 62 · see citing works

Co-delivery nanoparticle to overcome metastasis promoted by insufficient chemotherapy

Zhou, Q., Li, Y., Zhu, Y., Yu, C., Jia, H., Bao, B., Hu, H., Xiao, C., Zhang, J., Zeng, X., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.026 · Cited by 62 · see citing works

Epigenetic Reprogramming of TGF-β Signaling in Breast Cancer

Suriyamurthy, S., Baker, D. A., ten Dijke, P., & Iyengar, P. V. (2019) · Cancers · doi:10.3390/cancers11050726 · Cited by 62 · see citing works

In the Shadow of Fibrosis: Innate Immune Suppression Mediated by Transforming Growth Factor-β

Thomas, B. J., Kan‐o, K., Loveland, K. L., Elias, J. A., & Bardin, P. G. (2016) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0248ps · Cited by 61 · see citing works

Fibroblasts orchestrate cellular crosstalk in the heart through the ECM

Bowers, S., Meng, Q., & Molkentin, J. D. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00043-7 · Cited by 59 · see citing works

Biological approaches for hypertrophic scars

Zhong, L.-Z., Li, M.-R., & Fu, X.-B. (2019) · International Wound Journal · doi:10.1111/iwj.13286 · Cited by 50 · see citing works

Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer

Busenhart, P., Montalban‐Arques, A., Katkeviciutė, E., Morsy, Y., Passen, C. V., Hering, L., Atrott, K., Lang, S., Garzon, J. F. G., Naschberger, E., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003465 · Cited by 58 · see citing works

Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade

Greco, R., Qu, H., Qu, H., Theilhaber, J., Shapiro, G., Gregory, R. C., Winter, C. G., Malkova, N. V., Sun, F. F., Jaworski, J. A., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1811605 · Cited by 58 · see citing works

Role of IL-17A in murine models of COPD airway disease

Yanagisawa, H., Hashimoto, M., Minagawa, S., Takasaka, N., Ma, R., Moermans, C., Ito, S., Araya, J., Budelsky, A., Goodsell, A., et al. (2016) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00301.2016 · Cited by 58 · see citing works

Different roles of interleukin 6 and interleukin 11 in the liver: implications for therapy

Widjaja, A. A., Chothani, S. P., & Cook, S. A. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1761203 · Cited by 54 · see citing works

MicroRNA applications for prostate, ovarian and breast cancer in the era of precision medicine

Smith, B., Agarwal, P., & Bhowmick, N. A. (2017) · Endocrine Related Cancer · doi:10.1530/erc-16-0525 · Cited by 56 · see citing works

Development of small molecule inhibitors targeting TGF-β ligand and receptor: Structures, mechanism, preclinical studies and clinical usage

Wang, H., Chen, M., Sang, X., You, X., Wang, Y., Paterson, I. C., Hong, W., & Yang, X. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112154 · Cited by 56 · see citing works

Targeting of the Cancer-Associated Fibroblast—T-Cell Axis in Solid Malignancies

Harryvan, T. J., Verdegaal, E. M. E., Hardwick, J. C. H., Hawinkels, L. J. A. C., & van der Burg, S. H. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111989 · Cited by 55 · see citing works

The effect of transforming growth factor-beta type I receptor kinase inhibition on the heart valves of Sprague-Dawley rats

Maratea, K. A. (2009) · Purdue e-Pubs (Purdue University System)

A Constitutive Mutation ofALK5Disrupts Cardiac Looping and Morphogenesis in Mice

Charng, M., Frenkel, P. A., Lin, Q., Yumada, M., Schwartz, R. J., Olson, E. N., Overbeek, P. A., & Schneider, M. D. (1998) · Developmental Biology · doi:10.1006/dbio.1998.8905 · Cited by 40 · see citing works

Inhibition of ALK5 Signaling Induces Physeal Dysplasia in Rats

Frazier, K. S., Thomas, R. A., Scicchitano, M. S., Mirabile, R. C., Boyce, R. W., Zimmerman, D. M., Grygielko, E. T., Nold, J. B., DeGouville, A.-C., Huet, S., et al. (2007) · Toxicologic Pathology · doi:10.1080/01926230701198469 · Cited by 49 · see citing works

Signaling via the Tgf-β type I receptor Alk5 in heart development

Sridurongrit, S., Larsson, J., Schwartz, R. J., Ruiz‐Lozano, P., & Kaartinen, V. (2008) · Developmental Biology · doi:10.1016/j.ydbio.2008.07.038 · Cited by 158 · see citing works

Activin receptor-like kinase 2 and Smad6 regulate epithelial–mesenchymal transformation during cardiac valve formation

Desgrosellier, J. S., Mundell, N. A., McDonnell, M. A., Moses, H. L., & Barnett, J. V. (2005) · Developmental Biology · doi:10.1016/j.ydbio.2004.12.037 · Cited by 88 · see citing works